Latest Information Update: 16 Jul 2007
At a glance
- Originator UCB
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 08 Dec 2003 Preclinical trials in Inflammation in United Kingdom (PO)